Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now later-stage tilt small index

Neurocognitive Disorders: later-stage trial registry

4 of 9 indexed Neurocognitive Disorders trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Neurocognitive Disorders: 9 US clinical trials tracked, 4 recruiting.

Neurocognitive Disorders is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan, running 2 of these trials.

Enrollment posture brief

Registry condition neurocognitive-disorders

OPEN 4 | RECR 44% | LATE 2 | EARLY 0 | RANK #1916 | SPON 2

Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Neurocognitive Disorders (th…44%Acute Otitis Media22.2%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Neurocognitive Disorders

Neurocognitive Disorders lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Neurocognitive Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Neurocognitive Disorders is recruiting below its size-band peers.

    4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Neurocognitive Disorders research.

    University of Michigan accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Neurocognitive Disorders enrolment sits around 80 participants.

    Median target enrolment is 80 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Neurocognitive Disorders splits between interventional and observational designs.

    5 interventional and 4 observational studies make up this index (55.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 31Phase 41

Phase Distribution

PhaseTrial count
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Neurocognitive Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Blood Biomarkers Diagnostic test
1 trials
Cognitive testing Diagnostic test
1 trials
Brain Imaging Diagnostic test
1 trials
Harmony at HOME (H@H) Behavioral
1 trials
Usual care Psychoeducation Behavioral
1 trials
Modifiable lifestyle factors Behavioral
1 trials
CRT Behavioral
1 trials
Emerald Device Monitoring Device
1 trials

US sites by state

Facility locations filed on Neurocognitive Disorders trials. A trial with sites in several states counts in each.

California 3 trials
Michigan 2 trials
Florida 2 trials
Wisconsin 1 trials
Utah 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
Oregon 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Neurocognitive Disorders page

9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurocognitive Disorders condition card totals 9 registered trials; most-linked intervention Blood Biomarkers; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.